


All-oral regimen of ixazomib, lenalidomide, and dexamethasone represents an effective and tolerable treatment option for patients with relapsed/refractory multiple myeloma

Patients with relapsed/refractory multiple myeloma
phase 3 TOURMALINE-MM1 study



- Progression-free survival was prolonged with **Ixazomib-Rd** regardless of type of prior treatment
- Patients with 2 or 3 prior therapies, or 1 prior therapy without transplant had greater benefit than patients with 1 prior therapy and transplant